Analysts Conflicted on These Healthcare Names: Sensus Healthcare (SRTS), NeoGenomics (NEO) and COMPASS Pathways (CMPS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sensus Healthcare (SRTS – Research Report), NeoGenomics (NEO – Research Report) and COMPASS Pathways (CMPS – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sensus Healthcare (SRTS)
Maxim Group analyst Anthony Vendetti maintained a Buy rating on Sensus Healthcare on February 12 and set a price target of $6.00. The company’s shares closed last Friday at $3.86, close to its 52-week low of $3.09.
According to TipRanks.com, Vendetti has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sensus Healthcare with a $6.00 average price target, representing a 64.4% upside. In a report issued on February 13, Lake Street also reiterated a Buy rating on the stock with a $6.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
NeoGenomics (NEO)
William Blair analyst Andrew Brackmann reiterated a Hold rating on NeoGenomics today. The company’s shares closed last Friday at $11.38.
According to TipRanks.com, Brackmann is a 4-star analyst with an average return of
Currently, the analyst consensus on NeoGenomics is a Moderate Buy with an average price target of $14.50.
COMPASS Pathways (CMPS)
In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on COMPASS Pathways, with a price target of $19.00. The company’s shares closed last Friday at $5.81.
According to TipRanks.com, Brisebois is a 1-star analyst with an average return of
COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $18.50, a 214.1% upside from current levels. In a report issued on February 2, TipRanks – Google also reiterated a Buy rating on the stock with a $7.50 price target.
